Related Experiment Videos
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for
Houman Khakpour1, William H Frishman
1Department of Medicine, UCLA David Geffen School of Medicine/UCLA Medical Center, Los Angeles, CA, USA.
Insights
Cardiovascular disease (CVD) risk can be better identified using lipoprotein-associated phospholipase A2 (Lp-PLA2) levels. This emerging biomarker helps detect inflammation and CVD risk, even with normal cholesterol or C-reactive protein levels.
Area of Science:
- Cardiovascular medicine
- Inflammation research
- Biomarker discovery
Background:
- Cardiovascular disease (CVD) is a leading cause of death globally.
- Vascular inflammation, particularly in coronary arteries, contributes to plaque instability and cardiovascular events.
- Inflammation can persist in patients on statin therapy or with normal cholesterol levels, highlighting a clinical dilemma in risk assessment.
Purpose of the Study:
- To re-evaluate the role of inflammatory factors and biomarkers in identifying patients at risk for cardiovascular events.
- To explore Lipoprotein-associated phospholipase A2 (Lp-PLA2) as an emerging biomarker for vascular inflammation and CVD risk.
- To assess the utility of Lp-PLA2 measurement in improving cardiovascular risk identification, independent of traditional markers.
Main Methods:
- Review of current risk factors for cardiovascular disease, including C-reactive protein, fibrinogen, and platelet activator inhibitor-1.
- Examination of emerging evidence supporting Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a promoter of vascular inflammation.
- Analysis of studies correlating Lp-PLA2 levels with cardiovascular disease (CVD) and stroke rates.
Main Results:
- Higher levels of Lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with increased rates of cardiovascular disease (CVD) and stroke.
- Measurement of Lp-PLA2 can enhance the identification of individuals at increased risk for CVD.
- Lp-PLA2 provides risk stratification independent of cholesterol levels and C-reactive protein (CRP).
Conclusions:
- Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a significant emerging biomarker for vascular inflammation and cardiovascular risk.
- Measuring Lp-PLA2 levels offers an improved method for identifying at-risk individuals, complementing existing risk factors.
- Lp-PLA2 is a promising target for immunomodulatory therapies aimed at reducing atherosclerosis development and clinical events.
Abstract:
Cardiovascular disease (CVD) is the number one cause of death in both adult men and women. It is evident that active inflammation in the coronary arteries remains a key factor in plaque instability and subsequent cardiovascular events. The current clinical dilemma is that inflammation can occur even in patients who are on statin therapy, as well as in patients with "normal" cholesterol levels. Because fully half of all patients with cardiovascular events have normal cholesterol levels, there is a need to re-evaluate the role of inflammatory factors and biomarkers to better identify patients at risk. Current risk factors include C-reactive protein, fibrinogen, and platelet activator inhibitor-1. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is another emerging risk factor. The weight of evidence suggests that this biomarker also promotes vascular inflammation. Patients with higher levels of Lp-PLA2 have higher rates of CVD and stroke. Measurement of Lp-PLA2 can improve the identification of people at increased risk for CVD, independent of cholesterol, or C-reactive protein level. Lp-PLA2 has been an innovative target of immunomodulation therapy, and clinical studies with specific inhibitors are in progress evaluating this approach for both atherosclerosis development and clinical event reduction.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Pharmacogenomics: Identification of New Drug Targets
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
01:26Atherosclerosis III: Management
01:38Inflammation